Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 11/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 5/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | GCK | P35557 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5423439 | 0.85 | MEN1 (0.43) | CHRM4MAOBSMN1; SMN2 | |
| SCHEMBL5420860 | 0.83 | KDR (0.34) | CHRM4KDRMAPK14TNNI3KSMN1; SMN2 | |
| SCHEMBL5415271 | 0.80 | MAP4K4 (0.45) | CHRM4MAOBSMN1; SMN2L3MBTL1MAOA | |
| SCHEMBL5402357 | 0.79 | POLB (0.46) | MAOBMAOAPOLBMAPK1HSD17B10 | |
| SCHEMBL5413428 | 0.78 | L3MBTL1 (0.40) | CHRM4MAOBSMN1; SMN2L3MBTL1MAOA | |
| SCHEMBL5413305 | 0.77 | SMN1; SMN2 (0.54) | MAOBSMN1; SMN2L3MBTL1MAOA | |
| SCHEMBL5404834 | 0.76 | KMO (0.39) | MAOBMAOAHSD17B10 | |
| SCHEMBL5402360 | 0.75 | CHRNA7 (0.46) | MAOBL3MBTL1MAOA | |
| SCHEMBL17282973 | 0.75 | NPC1 (0.38) | MAOBMAOAPOLBMAPK1HSD17B10 | |
| SCHEMBL5413024 | 0.74 | MAP4K4 (0.45) | MAOBSMN1; SMN2L3MBTL1MAPK1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7291730-B2 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-11-06 | — | — | US | disclosed |
| US-20050107609-A1 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY | 2005-05-19 | — | — | US | disclosed |
| US-6838463-B2 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-01-04 | — | — | US | disclosed |
| EP-1366026-B1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS PESTICIDES | SUMITOMO CHEMICAL CO (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-20040077669-A1 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-04-22 | — | — | US | disclosed |
| EP-1366026-A2 | PYRIMIDINE COMPOUNDS AND THEIR USE | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002024663-A2 | PYRIMIDINE COMPOUNDS AND THEIR USE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107609-A1 | Pyrimidine compounds and their use | TYMP, TYMS, UMPS | CHRM4 1229/4885MAOB 907/4885KDR 872/4885 |
| US-20040077669-A1 | Pyrimidine compounds and their use | TYMP, TYMS, DPYD | CHRM4 2249/4885MAOB 1563/4885KDR 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.